[Is familial hypercholesterolemia under control in the Czech Republic?]
Related Experiment Video
Updated: Jul 13, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
1Genetická laborator Centra kardiovaskulární a transplantacní chirurgie Brno. tomas.freiberger@cktch.cz
Insights
Early diagnosis and treatment of familial hypercholesterolemia (FH) are crucial for preventing premature atherosclerosis deaths. The Czech Republic
Area of Science:
- Cardiology
- Genetics
- Public Health
Context:
- Czech Republic joined the MedPed initiative in 1997.
- Familial hypercholesterolemia (FH) poses a significant risk for premature atherosclerosis.
- A network of specialized centers for severe dyslipidemias was established.
Purpose:
- To reduce mortality from premature atherosclerosis in FH patients.
- To emphasize timely diagnosis and hypolipidemic therapy for FH.
- To increase screening rates within affected families.
Summary:
- 3,208 cases of dyslipidemia detected in 2,377 families, representing 16% of estimated FH patients.
- Current FH diagnosis and treatment rates within families are low (1.3 patients per family).
- Significant progress made, but FH remains inadequately controlled in the Czech Republic.
Impact:
- Aims to dramatically increase FH screening and diagnosis rates.
- Seeks to improve management of FH and reduce associated cardiovascular risks.
- Enhancing early detection and treatment to prevent premature deaths from atherosclerosis.
Abstract:
In 1997, the Czech Republic joined the international project MedPed (Make early diagnosis to Prevent early deaths), the principal objective of which is to dramatically reduce the number of deaths caused by the premature clinical manifestations of atherosclerosis in patients with familial hypercholesterolemia (FH). Stress has been laid on a timely diagnosis, especially in family members of patients who have already been diagnosed with the disease, and on timely application of adequate hypolipidemic therapy. A network of centres dealing with severe inborn dyslipidemias has been set up under the auspices of the Czech Society for Atherosclerosis. As many as 3,208 cases of dyslipidemia from 2377 families have been detected thanks to the network and to the contribution of cooperating doctors; this represents 16% of the estimated number of 20,000 patients with FH in this country. However, the disease is far from being under control in the Czech Republic. The principal objective for the immediate future is to dramatically increase the number of people screened within affected families; thus multiplying the current rate of diagnosed and treated patients with FH within each family from its current value of 1.3.
Related Concept Videos
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Pharmacogenomics: Identification of New Drug Targets
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Lipid Catabolism
